- Home
- AQST vs RIGL Comparison
AQST vs RIGL Comparison
Compare AQST & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQST
- RIGL
- Stock Information
- Founded
- AQST 2004
- RIGL 1996
- Country
- AQST United States
- RIGL United States
- Employees
- AQST N/A
- RIGL N/A
- Industry
- AQST Biotechnology: Pharmaceutical Preparations
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- AQST Health Care
- RIGL Health Care
- Exchange
- AQST Nasdaq
- RIGL Nasdaq
- Market Cap
- AQST 254.1M
- RIGL 298.0M
- IPO Year
- AQST 2018
- RIGL 2000
- Fundamental
- Price
- AQST $2.51
- RIGL $16.85
- Analyst Decision
- AQST Strong Buy
- RIGL Buy
- Analyst Count
- AQST 6
- RIGL 5
- Target Price
- AQST $11.17
- RIGL $36.80
- AVG Volume (30 Days)
- AQST 1.4M
- RIGL 248.5K
- Earning Date
- AQST 05-06-2025
- RIGL 05-06-2025
- Dividend Yield
- AQST N/A
- RIGL N/A
- EPS Growth
- AQST N/A
- RIGL N/A
- EPS
- AQST N/A
- RIGL 0.99
- Revenue
- AQST $57,561,000.00
- RIGL $179,278,000.00
- Revenue This Year
- AQST N/A
- RIGL $12.53
- Revenue Next Year
- AQST $39.51
- RIGL $15.68
- P/E Ratio
- AQST N/A
- RIGL $17.02
- Revenue Growth
- AQST 13.79
- RIGL 54.71
- 52 Week Low
- AQST $2.20
- RIGL $7.48
- 52 Week High
- AQST $5.80
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- AQST 41.88
- RIGL 41.36
- Support Level
- AQST $2.20
- RIGL $16.05
- Resistance Level
- AQST $2.61
- RIGL $17.67
- Average True Range (ATR)
- AQST 0.22
- RIGL 1.31
- MACD
- AQST -0.03
- RIGL 0.02
- Stochastic Oscillator
- AQST 36.47
- RIGL 45.76
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.